Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : VET3-TGI,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
KaliVir Doses First Patient in Trial of VET3-TGI For Advanced Solid Tumors
Details : VET3-TGI is an oncolytic immunotherapy, given intratumoraly, that acts as a TGF beta-1 inhibitor & IL-12 stimulator, is being studied in combination with pembrolizumab for treating solid tumors.
Brand Name : VET3-TGI
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 08, 2024
Lead Product(s) : VET3-TGI,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : VET3-TGI,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
KaliVir Immunotherapeutics Gets FDA Clearance for VET3-TGI Oncolytic Immunotherapy
Details : VET3-TGI is an oncolytic immunotherapy, given intratumoraly, that acts as a TGF beta-1 inhibitor & IL-12 stimulator, is being studied in combination with pembrolizumab for treating solid tumors.
Brand Name : VET3-TGI
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 01, 2024
Lead Product(s) : VET3-TGI,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ASP1012
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ASP1012 (formerly named VET2-L2) is a systemic oncolytic vaccinia virus therapy in which the virus is delivered intravenously and expresses Leptin-IL2 fusion protein as a therapeutic payload. The trial is expected to begin in Q1 2024.
Brand Name : ASP1012
Molecule Type : Vaccine
Upfront Cash : Not Applicable
October 24, 2023
Lead Product(s) : ASP1012
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Vaccinia-based Cancer Therapy,Tecovirimat
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : SIGA Technologies
Deal Size : Undisclosed
Deal Type : Collaboration
SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics
Details : TPOXX is a powerful antiviral drug to vaccinia and allows the safe use of higher doses of vaccinia vectors, there is also the potential it could increase immunotherapeutic outcomes.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 15, 2022
Lead Product(s) : Vaccinia-based Cancer Therapy,Tecovirimat
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : SIGA Technologies
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : VET-ROG1
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : F. Hoffmann-La Roche
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, KaliVir will generate oncolytic vaccinia virus product candidates derived from the company's VETTM platform, including VET-ROG1 expressing Roche proprietary therapeutic transgenes.
Brand Name : VET-ROG1
Molecule Type : Large molecule
Upfront Cash : Undisclosed
May 23, 2022
Lead Product(s) : VET-ROG1
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : F. Hoffmann-La Roche
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : VET2-L2
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Astellas Pharma
Deal Size : $634.0 million
Deal Type : Collaboration
Details : Under the terms of the agreement, Astellas will pay to KaliVir up to US$56 million in the form of an upfront payment and other payments to support research and preclinical activities related to VET2-L2 and the Second Product.
Brand Name : VET2-L2
Molecule Type : Large molecule
Upfront Cash : $56.0 million
December 07, 2020
Lead Product(s) : VET2-L2
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Astellas Pharma
Deal Size : $634.0 million
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?